Fortress Biotech Crecimiento futuro

Future controles de criterios 2/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Fortress Biotech de 67.3% y 55.9% respectivamente, mientras que el BPA crecerá en un 77.7% al año.

Información clave

67.3%

Tasa de crecimiento de los beneficios

77.7%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	28.3%
Tasa de crecimiento de los ingresos	55.9%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	19 Nov 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Fortress Biotech, Inc.'s (NASDAQ:FBIO) Shares Bounce 36% But Its Business Still Trails The Industry

Oct 29

Fortress Biotech, Inc. (NASDAQ:FBIO) Held Back By Insufficient Growth Even After Shares Climb 54%

Jul 26

There's No Escaping Fortress Biotech, Inc.'s (NASDAQ:FBIO) Muted Revenues Despite A 99% Share Price Rise

Dec 29

There Is A Reason Fortress Biotech, Inc.'s (NASDAQ:FBIO) Price Is Undemanding

Aug 18

Fortress to get NIH funding for trial of Triplex vaccine to prevent CMV in liver transplant patients

Aug 11

David Jin is the new finance chief of Fortress Biotech

Jul 22

Previsiones de crecimiento de beneficios e ingresos

NasdaqCM:FBIO - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	240	4	N/A	N/A	1
12/31/2025	136	-36	N/A	N/A	2
12/31/2024	58	-60	N/A	N/A	2
9/30/2024	82	-58	-102	-102	N/A
6/30/2024	83	-49	-100	-99	N/A
3/31/2024	85	-63	-113	-110	N/A
12/31/2023	85	-69	-136	-128	N/A
9/30/2023	62	-86	-150	-141	N/A
6/30/2023	63	-104	-176	-168	N/A
3/31/2023	64	-100	-182	-176	N/A
12/31/2022	76	-95	-202	-179	N/A
9/30/2022	78	-97	-196	-170	N/A
6/30/2022	82	-93	-181	-149	N/A
3/31/2022	81	-74	-179	-142	N/A
12/31/2021	69	-65	-133	-117	N/A
9/30/2021	64	-38	-113	-98	N/A
6/30/2021	53	-33	-110	-101	N/A
3/31/2021	44	-43	-89	-83	N/A
12/31/2020	46	-47	-91	-84	N/A
9/30/2020	43	-57	-99	-88	N/A
6/30/2020	43	-54	-92	-81	N/A
3/31/2020	43	-54	-102	-92	N/A
12/31/2019	37	-40	-104	-95	N/A
9/30/2019	34	-45	-98	-92	N/A
6/30/2019	30	-51	-106	-101	N/A
3/31/2019	27	-53	-105	-96	N/A
12/31/2018	27	-73	-108	-99	N/A
9/30/2018	-107	-61	-107	-98	N/A
6/30/2018	-65	-69	N/A	-98	N/A
3/31/2018	-22	-72	N/A	-98	N/A
12/31/2017	17	-65	N/A	-81	N/A
9/30/2017	155	-74	N/A	-78	N/A
6/30/2017	109	-60	N/A	-62	N/A
3/31/2017	61	-55	N/A	-46	N/A
12/31/2016	16	-55	N/A	-46	N/A
9/30/2016	4	-50	N/A	-35	N/A
6/30/2016	3	-55	N/A	-31	N/A
3/31/2016	1	-49	N/A	-30	N/A
12/31/2015	1	-48	N/A	-20	N/A
9/30/2015	1	-40	N/A	-17	N/A
6/30/2015	1	-27	N/A	-14	N/A
3/31/2015	1	-25	N/A	-12	N/A
12/31/2014	N/A	-20	N/A	-16	N/A
9/30/2014	N/A	-26	N/A	-20	N/A
6/30/2014	N/A	-30	N/A	-24	N/A
3/31/2014	N/A	-36	N/A	-28	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que FBIO siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que FBIO siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que FBIO siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (55.9% al año) de FBIO crezcan más rápidamente que los del mercado US (8.9% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (55.9% al año) de FBIO crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de FBIO se prevé que sea elevada dentro de 3 años.

Fortress Biotech Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Forecast to breakeven in 2026

Consensus revenue estimates fall by 24%

Consensus revenue estimates increase by 41%

Price target increased by 7.7% to US$14.00

Consensus EPS estimates fall by 93%, revenue upgraded

No longer forecast to breakeven

Recent updates

Forecast to breakeven in 2026

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Fortress Biotech, Inc.'s (NASDAQ:FBIO) Shares Bounce 36% But Its Business Still Trails The Industry

Consensus revenue estimates fall by 24%

Fortress Biotech, Inc. has completed a Follow-on Equity Offering in the amount of $6.5 million.

Fortress Biotech, Inc. announced that it has received $1.500001 million in funding

Fortress Biotech, Inc. has completed a Follow-on Equity Offering in the amount of $128 million.

Consensus revenue estimates increase by 41%

Second quarter 2024 earnings: EPS exceeds analyst expectations

Price target increased by 7.7% to US$14.00

New minor risk - Share price stability

Fortress Biotech, Inc. (NASDAQ:FBIO) Held Back By Insufficient Growth Even After Shares Climb 54%

Fortress Biotech, Inc. announced that it expects to receive $50 million in funding

Consensus EPS estimates fall by 93%, revenue upgraded

New major risk - Negative shareholders equity

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Fortress Biotech Announces First Patient Dosed in Multi-Center Phase 2 Study of Triplex for Control of CMV in Patients Undergoing Liver Transplantation

New major risk - Revenue and earnings growth

Fortress Biotech, Inc., Annual General Meeting, May 23, 2024

New minor risk - Profitability

No longer forecast to breakeven

Full year 2023 earnings: EPS and revenues exceed analyst expectations

New minor risk - Profitability

Eric Rowinsky Announces Not Stand for Re-Election to the Board of Fortress Biotech, Inc

Executive Chairman recently bought US$119k worth of stock

There's No Escaping Fortress Biotech, Inc.'s (NASDAQ:FBIO) Muted Revenues Despite A 99% Share Price Rise

Fortress Biotech, Inc. has filed a Follow-on Equity Offering in the amount of $11 million.

Price target increased by 27% to US$67.50

Price target decreased by 14% to US$50.00

Forecast to breakeven in 2024

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

New major risk - Shareholder dilution

Fortress Biotech, Inc. has completed a Composite Units Offering.

Fortress Biotech, Inc. has completed a Composite Units Offering.

Journey Medical Corporation Announces Data from Bioavailability Study of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 Mg) Vs. Solodyn (Minocycline Hydrochine Hydrochloride Extended-Release Tablets, 105 Mg)

New major risk - Share price stability

Fortress Biotech Announces Reverse Stock Split to Regain Compliance

Price target decreased by 8.1% to US$3.55

Consensus revenue estimates fall by 20%

There Is A Reason Fortress Biotech, Inc.'s (NASDAQ:FBIO) Price Is Undemanding

New major risk - Financial position

Second quarter 2023 earnings: EPS misses analyst expectations

Forecast breakeven date pushed back to 2025

Consensus revenue estimates increase by 36%

Price target decreased by 13% to US$4.34

Consensus revenue estimates fall by 40%

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Fortress Biotech Receives Second 180-Calendar Day Grace Period from Nasdaq to Regain Compliance with the Nasdaq Listing Rule 5550(a)(2)

Full year 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased by 16% to US$5.10

Fortress Biotech, Inc. has completed a Follow-on Equity Offering in the amount of $13.896816 million.

Fortress Biotech, Inc. Appoints Lucy Lu, M.D., to Its Board of Directors

Price target decreased to US$5.92

Executive Chairman recently bought US$68k worth of stock

No longer forecast to breakeven

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus forecasts updated

Insufficient new directors

Fortress Biotech Receives a Letter from the Listing Qualifications Staff of the Nasdaq Stock Market LLC

Executive Chairman recently bought US$70k worth of stock

Urica Therapeutics, Inc Appoints Seasoned Biotech Executive Jay D. Kranzler, M.D., Ph.D., as Chairman and Chief Executive Officer

Consensus revenue estimates fall by 13%

Second quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Fortress to get NIH funding for trial of Triplex vaccine to prevent CMV in liver transplant patients

Fortress Biotech, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Fortress Biotech Inc. Appoints David Jin as Chief Financial Officer

David Jin is the new finance chief of Fortress Biotech

Price target decreased to US$6.10